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In a previous study, we showed that EGFR mutation status in serum 
DNA was useful as a predictor of response to geﬁtinib (IRESSA). The 
aim of this study was to assess the feasibility of detecting EGFR muta-
tions in serum DNA and to evaluate the usefulness of EGFR mutation 
status in serum DNA as a means of predicting a beneﬁt from geﬁtinib 
therapy in Japanese patients with NSCLC. We obtained pairs of tumor 
and serum samples from 42 patients treated with geﬁtinib and exam-
ined them for EGFR mutations. EGFR mutation status was determined 
by a direct sequencing method and by Scorpion Ampliﬁcation Refrac-
tory Mutation System (ARMS) technology. EGFR mutations were de-
tected in the tumor samples of eight patients and in the serum samples 
of seven patients. EGFR mutation status in the tumors and serum 
samples was consistent in 39 (92.9%) of the 42 pairs. EGFR! mutations 
were more frequent in women and non-smokers, and there were strong 
correlations between both EGFR mutation status in the tumor samples 
and serum samples, and objective response to geﬁtinib (p<0.001, Fish-
er’s exact test). Median progression-free survival time was signiﬁcantly 
longer in the patients with EGFR mutations than in the patients without 
EGFR mutations (194 vs. 55 days, P=0.016, in tumor samples; 174 vs. 
58 days, P=0.044, in serum samples, Log-rank test). Median survival 
time was longer in the patients with EGFR mutations detected by either 
of the two methods than in the patients without EGFR mutations, but 
the difference was not statistically signiﬁcant. The results suggest that 
it is feasible to use serum DNA to detect EGFR mutations, and that 
it’s potential as a predictor of response to, and survival on geﬁtinib is 
worthy of further evaluation.
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Epidermal growth factor receptor (EGFR) gene mutational status 
and response to gefitinib in patients with non-small cell lung 
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Background: Somatic EGFR gene mutations are reported to be associ-
ated with clinical responses to geﬁtinib and erlotinib in patients with 
non-small cell lung cancer (NSCLC). Retrospective studies have shown 
around 75% response rate in patients with tumors that have EGFR gene 
mutations compared with a response rate of less than 10% in those with 
wild-type EGFR. We prospectively examined the status of EGFR gene 
mutations in patients with NSCLC and their response to treatment with 
geﬁtinib. 
Methods: Clinical samples (formalin-ﬁxed parafﬁn-embedded tumor 
tissue, pleural effusion, and sputum) were obtained with informed con-
sent from patients with advanced NSCLC at Toranomon Hospital, and 
were examined for EGFR mutations by direct sequencing or the peptide 
nucleic acid-locked nucleic acid PCR clamp method (Cancer Res. 
2005;65:7276). Patients who received geﬁtinib therapy after examin-
ing EGFR mutations were then evaluated for their response to geﬁtinib 
according to RECIST criteria. 
Results: Tumor samples from 60 patients who were enrolled in the 
study from June 2006 to January 2007 were analyzed. EGFR muta-
tions were detected in 17 of 60 patients (28.3%) (13 females/4 males; 
16 never-smokers/ 1 former-smoker; all adenocarcinomas). Detected 
mutations included 9- to 18-base deletion in exon 19 in 12 patients 
(70.6%), L858R in exon 21 in 4 (23.5%) and an 18-base insertion in 
exon 19 in 1 (5.9%), respectively. Ten of 17 patients with EGFR muta-
tions were given geﬁtinib 250 mg daily (median age: 67 years; 9 fe-
males/1 male; all never-smokers; performance status 0-1/2-4=6/4; stage 
IIIB/IV/postoperative recurrence=2/3/5). Four patients were treated 
with geﬁtinib as the ﬁrst-line therapy. Nine patients had measurable le-
sions, and the response to geﬁtinib was PR in four patients, SD in three, 
and PD in two, respectively. The response rate and disease control 
rate were 44.4% and 77.8%, respectively. On the other hand, four of 
43 patients with wild-type EGFR received geﬁtinib, but none of these 
patients achieved CR or PR. No signiﬁcant adverse events (>grade 3) 
including acute lung injury/interstitial pneumonia were observed. 
Conclusion: EGFR mutations were found in the tumors of 28% of 
Japanese patients with NSCLC. The disease control rate of geﬁtinib 
therapy was extremely good in those who had EGFR mutations. Thus, 
routine evaluation for the EGFR mutation status is desirable in patients 
with NSCLC before treatment of geﬁtinib. 
P3-105 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Response to erlotinib in the neoadjuvant setting for early stage 
non-small cell lung cancer (NSCLC): a case report
Kappers, Ingrid1 Burgers, Jacobus A.2 Rijna, Herman3 Codrington, 
Henk E.4 Dingemans, Anne-Marie5 Weenink, Carla6 Wouters, Michel J.1 
Valdes Olmos, Renato A.7 Zandwijk, Nico v.2 Klomp, Houke M.1 
1 The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 
Dept. of Surgical Oncology, Amsterdam, The Netherlands 2 Netherlands 
Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Thoracic 
Oncology, Amsterdam, The Netherlands 3 Kennemer Gasthuis, Dept. of 
Surgery, Haarlem, The Netherlands 4 Haga Hospital, Dept. of Pulmon-
ology, The Hague, The Netherlands 5 Academic Hospital Maastricht, 
Dept. of Thoracic Oncology, Maastricht, The Netherlands 6 Kennemer 
Gasthuis, Dept. of Pulmonology, Haarlem, The Netherlands 7 Neth-
erlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of 
Nuclear Medicine, Amsterdam, The Netherlands 
Background: Erlotinib as single agent is associated with objective 
response rates of about 12% in unselected patients with NSCLC stage 
IIIB/IV. Much higher response rates were observed in selected groups 
of patients selected on the basis of EGFR mutations. To investigate 
whether erlotinib is able to make an extra contribution to surgical 
treatment of early stage NSCLC, a phase II study was initiated in the 
Netherlands. This study is meant to provide a proof of principle if erlo-
tinib is a worthwhile induction therapy option and if erlotinib may be 
advised as induction regimen for a selected group of patients. We report 
a remarkable response in one of our ﬁrst patients.
Case Presentation: A 58-year old woman presenting with a clinical 
stage I adenocarcinoma in the right upper lobe was asked to participate 
in the study. After written informed consent, she received erlotinib for 
